Adiponectin protects against the development of systolic dysfunction following myocardial infarction.

[1]  I. Shiojima,et al.  Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. , 2006, Genes & development.

[2]  Takamitsu Nakamura,et al.  Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. , 2006, American journal of physiology. Heart and circulatory physiology.

[3]  S. Kihara,et al.  Adiponectin Replenishment Ameliorates Obesity-Related Hypertension , 2006, Hypertension.

[4]  I. Shiojima,et al.  Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload , 2006, Hypertension.

[5]  E. Ingelsson,et al.  Adiponectin and risk of congestive heart failure. , 2006, Journal of the American Medical Association (JAMA).

[6]  Y. Sharabi,et al.  Circulating adiponectin concentrations in patients with congestive heart failure , 2006, Heart.

[7]  Jan Frystyk,et al.  Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure , 2005, Circulation.

[8]  S. Kihara,et al.  Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms , 2005, Nature Medicine.

[9]  T. Funahashi,et al.  Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. , 2005, Cardiovascular research.

[10]  I. Shiojima,et al.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.

[11]  R. Karch,et al.  The spatial pattern of coronary capillaries in patients with dilated, ischemic, or inflammatory cardiomyopathy. , 2005, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[12]  H. Sumino,et al.  Adiponectin Replacement Therapy Attenuates Myocardial Damage in Leptin-deficient Mice with Viral Myocarditis , 2005, The Journal of international medical research.

[13]  S. Kihara,et al.  Adiponectin-mediated modulation of hypertrophic signals in the heart , 2004, Nature Medicine.

[14]  S. Kihara,et al.  Adiponectin Stimulates Angiogenesis in Response to Tissue Ischemia through Stimulation of AMP-activated Protein Kinase Signaling* , 2004, Journal of Biological Chemistry.

[15]  T. Ogihara,et al.  Hypoadiponectinemia Is an Independent Risk Factor for Hypertension , 2004, Hypertension.

[16]  S. Kihara,et al.  Selective Suppression of Endothelial Cell Apoptosis by the High Molecular Weight Form of Adiponectin , 2004, Circulation research.

[17]  S. Kihara,et al.  Adiponectin Stimulates Angiogenesis by Promoting Cross-talk between AMP-activated Protein Kinase and Akt Signaling in Endothelial Cells* , 2004, Journal of Biological Chemistry.

[18]  Robert Wolk,et al.  Body Mass Index: A Risk Factor for Unstable Angina and Myocardial Infarction in Patients With Angiographically Confirmed Coronary Artery Disease , 2003, Circulation.

[19]  H. Mizuguchi,et al.  Postinfarction Treatment With an Adenoviral Vector Expressing Hepatocyte Growth Factor Relieves Chronic Left Ventricular Remodeling and Dysfunction in Mice , 2003, Circulation.

[20]  Hitoshi Nishizawa,et al.  Reciprocal Association of C-Reactive Protein With Adiponectin in Blood Stream and Adipose Tissue , 2003, Circulation.

[21]  D. Levy,et al.  Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function: Sex-Related Differences in the Framingham Heart Study , 2003, Circulation.

[22]  S. Kihara,et al.  Association of Hypoadiponectinemia With Coronary Artery Disease in Men , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[23]  D. Levy,et al.  Obesity and the risk of heart failure. , 2003, The New England journal of medicine.

[24]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[25]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[26]  S. Kihara,et al.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[27]  W. Koch,et al.  Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.

[28]  Richard T. Lee,et al.  Endothelial Nitric Oxide Synthase Limits Left Ventricular Remodeling After Myocardial Infarction in Mice , 2001, Circulation.

[29]  P. Galuppo,et al.  Improvement of Left Ventricular Remodeling and Function by Hydroxymethylglutaryl Coenzyme A Reductase Inhibition With Cerivastatin in Rats With Heart Failure After Myocardial Infarction , 2001, Circulation.

[30]  A Hofman,et al.  The prognosis of heart failure in the general population: The Rotterdam Study. , 2001, European heart journal.

[31]  S. Anker,et al.  Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. , 2000, International journal of cardiology.

[32]  F. Eberli,et al.  Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. , 2000, American journal of physiology. Heart and circulatory physiology.

[33]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[34]  J. Cohn,et al.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. , 2000, Journal of the American College of Cardiology.

[35]  R. Kitsis,et al.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. , 2000, Circulation.

[36]  T Nakamura,et al.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. , 1999, Circulation.

[37]  S. Anker,et al.  Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. , 1999, Current opinion in cardiology.

[38]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[39]  J. Isner,et al.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. , 1998, Circulation.

[40]  W. MacLellan,et al.  Death by design. Programmed cell death in cardiovascular biology and disease. , 1997, Circulation research.

[41]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[42]  Philipp E. Scherer,et al.  A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes (*) , 1995, The Journal of Biological Chemistry.

[43]  M. Pfeffer,et al.  Progressive ventricular remodeling in rat with myocardial infarction. , 1991, The American journal of physiology.

[44]  D. Levy,et al.  The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. , 1991, JAMA.